Immunome Inc
NASDAQ:IMNM

Watchlist Manager
Immunome Inc Logo
Immunome Inc
NASDAQ:IMNM
Watchlist
Price: 24.75 USD -3.7% Market Closed
Market Cap: $2.3B

Net Margin

-2 301.3%
Current
Declining
by 570.3%
vs 3-y average of -1 731%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-2 301.3%
=
Net Income
$-222.7m
/
Revenue
$9.7m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-2 301.3%
=
Net Income
$-222.7m
/
Revenue
$9.7m

Peer Comparison

Country Company Market Cap Net
Margin
US
Immunome Inc
NASDAQ:IMNM
2.3B USD
Loading...
FR
Pharnext SCA
OTC:PNEXF
6T USD
Loading...
US
Abbvie Inc
NYSE:ABBV
387B USD
Loading...
US
Amgen Inc
NASDAQ:AMGN
184.5B USD
Loading...
US
Gilead Sciences Inc
NASDAQ:GILD
174.7B USD
Loading...
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
121.5B USD
Loading...
US
Epizyme Inc
F:EPE
94.1B EUR
Loading...
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
79.2B USD
Loading...
AU
CSL Ltd
ASX:CSL
86.9B AUD
Loading...
NL
argenx SE
XBRU:ARGX
43.2B EUR
Loading...
US
Seagen Inc
F:SGT
39.3B EUR
Loading...

Market Distribution

Lower than 95% of companies in the United States of America
Percentile
5th
Based on 15 072 companies
5th percentile
-2 301.3%
Low
-4 418 600% — -9.6%
Typical Range
-9.6% — 11.3%
High
11.3% — 1 135 400%
Distribution Statistics
the United States of America
Min -4 418 600%
30th Percentile -9.6%
Median 3.1%
70th Percentile 11.3%
Max 1 135 400%

Immunome Inc
Glance View

Market Cap
2.3B USD
Industry
Biotechnology

Immunome, Inc. is a biopharmaceutical company, which engages in the discovery and development of antibody therapeutics products. The company is headquartered in Exton, Pennsylvania and currently employs 39 full-time employees. The company went IPO on 2020-10-02. The firm's primary focus areas are oncology and infectious diseases. Its discovery platform identifies therapeutic antibodies and their targets by leveraging components of the immune system, memory B cells, from patients who have learned to fight off their disease. Its lead discovery programs include IMM-ONC-01 and IMM-BCP-01. IMM-ONC-01, is its lead oncology program, which is focused on IL-38. IMM-BCP-01, is its lead infectious disease discovery program with a focus on SARS-CoV-2, the virus that causes COVID-19. The firm is developing an antibody cocktail product candidate by identifying a combination of anti-viral antibodies produced by B cells from COVID-19 super-responders.

IMNM Intrinsic Value
5.56 USD
Overvaluation 78%
Intrinsic Value
Price
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-2 301.3%
=
Net Income
$-222.7m
/
Revenue
$9.7m
What is Immunome Inc's current Net Margin?

The current Net Margin for Immunome Inc is -2 301.3%, which is below its 3-year median of -1 731%.

How has Net Margin changed over time?

Over the last 2 years, Immunome Inc’s Net Margin has decreased from -1 277.1% to -2 301.3%. During this period, it reached a low of -3 240.4% on Dec 31, 2024 and a high of -215.6% on Sep 30, 2023.

Back to Top